Nora Lee Cothran, OD, FAAO, reviews a study which found a statistically significant reduction in IOP in patients with open-angle glaucoma and ocular hypertension when switching to latanoprostene bunod.
Nora Lee Cothran, OD, FAAO
Advertisement
Articles by Nora Lee Cothran, OD, FAAO
AOA 2025: Innovation and education take forefront at Optometry's Meeting
ByClark Y. Chang, OD, MSA, MSc, FAAO,Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO,Mila Ioussifova, OD, FAAO,Jessilin Quint, OD, MBA, MS, FAAO,Nora Lee Cothran, OD, FAAO,Devin Sasser, OD,Doerte Luensmann, PhD, Dipl Ing (AO), FAAO,Jacob R. Lang, OD, FAAO,Carolyn Majcher, OD, FAAO,Jordana Joy, Editor
ODs reflect on their time in Minneapolis, Minnesota, citing continuing education, tech updates, and networking opportunities as valued takeaways from the meeting.
Nora Lee Cothran, OD, FAAO, discussed the importance of optometrists addressing mental health with patients in their chair.
Nora Lee Cothran, OD, FAAO, moderated an Innovation Hub panel that featured 3 companies, giving insights into what's to come in the optometric industry.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
AAOpt 2026: Demodex tied to worse MGD as dry eye questionnaires miss blepharitis
2
AAOpt 2026: Aflibercept 8 mg extends RVO dosing as Amsler misses AMD damage
3
AAOpt 2026: The real-world impact of treatment switch to latanoprostene bunod
4
AAOpt 2026: Patient-reported blurred vision improvement with Vevye
5